>>CAMBRIDGE, Mass., Oct. 16 /PRNewswire/ -- Variagenics, Inc. (Nasdaq: VGNX - news), a leader in pharmacogenomics, today announced that it has named Jay Mohr to the position of Vice President, Business Development and Marketing and John Frey, Ph.D. to Senior Director, Regulatory Affairs & Clinical Informatics. Mohr will oversee the Company's marketing and business development teams, while managing worldwide strategic partnership collaborations within the biopharmaceutical and pharmaceutical industries. In a newly-established position at Variagenics, Dr. Frey will head the Company's regulatory affairs, biostatistics and clinical information sciences functions. He will also serve as the Company's Corporate Privacy Officer, ensuring ethical privacy and confidentiality protection for participants in Variagenics' research and development programs.
``Jay and John join Variagenics at an opportune time in our company's business development cycle, as well as in the pharmacogenomics market overall where this discipline continues to receive growing acceptance,'' said Taylor J. Crouch, President and CEO of Variagenics. ``Jay has been successful in driving biopharmaceutical product franchises to high levels of sales and profitability, and it's this degree of commitment and expertise that he will bring to Variagenics. John fills a key strategic regulatory role within our company and will provide critical leadership in effectively positioning Variagenics and our development programs with the FDA and regulatory agencies worldwide.''
Prior to coming to Variagenics, Mohr served as Executive Vice President of Serono, Inc.'s Metabolic Endocrinology Strategic Business Unit (North America) where he assumed head of commercial operations responsibilities for the $175 million recombinant human growth hormone franchise (SEROSTIM® and SAIZEN®). Under Mohr's three year leadership, cumulative sales for the franchise doubled. During his tenure in this position he led an integrated team of 110 sales and marketing professionals as well as clinical science and medical directors for North America. This position also included strategic licensing and R&D responsibilities. While at Serono, Mohr also held various senior management positions in the company's Metabolic and Immune Therapy and MS Strategic Business Units. Before joining Serono he was with Schering- Plough, Price Waterhouse (now PricewaterhouseCoopers LLP), Marketing Corp. of America and HBO & Company, serving in various management capacities.
Dr. Frey has 29 years of progressive accomplishments and experience developing pharmaceuticals and medical devices from clinical development through attaining marketing approval. His experience also includes management positions within R&D, biostatistics, new product development, clinical, scientific affairs, and regulatory affairs for pharmaceutical, CRO, and medical device companies including, Pfizer, Inc., Bristol-Myers International Division (now Bristol-Myers Squibb), Johnson & Johnson, and Ciba-Geigy (now Novartis Corporation). Dr. Frey had direct involvement in developing and attaining FDA and international registration of cardiovascular, oncology, OB/GYN, metabolic, CNS, pulmonary, and anti-infective pharmaceutical products and medical devices.
Mr. Mohr is a graduate of the Wharton School at the University of Pennsylvania, where he received his M.B.A., and Vanderbilt University where he received a B.A. Dr. Frey received his Ph.D. in Genetics and Biostatistics from Purdue University, where he was also an NIH fellow in Biometry. He also holds an M.S. in Genetics and Biostatistics from Oklahoma State University, and a B.S. from Pennsylvania State University.<<
snip
Cheers, Tuck |
